CD19 is a B-lineage-restricted surface antigen expressed on normal and malignant B cells, making it a widely explored target for immunotherapy, particularly CD19-directed CAR-T cell therapy. The FMC63 monoclonal antibody, a mouse IgG2a antibody specific for CD19, is one of the most widely used sources for generating CD19-targeting CAR antigen-binding domains. The FMC63-derived single-chain variable fragment (scFv) plays a critical role in antigen recognition and has been incorporated into numerous CD19 CAR-T constructs.

AntibodySystem provides a comprehensive portfolio of research reagents supporting CD19 FMC63 scFv and CAR-T development studies. Our product portfolio includes Anti-Human CD19 scFv Antibody (FMC63), a panel of anti-FMC63 scFv monoclonal antibodies with multiple fluorochrome conjugates for flow cytometry analysis, and a CAR Immunogenicity ELISA Kit for quantitative evaluation of immune responses against CAR components. These reagents are validated for ELISA, flow cytometry, Western blot, and CAR-related research applications, supporting CAR construct characterization, immunogenicity assessment, and quality control studies.